Evaluating the Likelihood to be Helped or Harmed after Treatment with Viloxazine Extended-Release in Children and Adolescents with Attention Deficit/Hyperactivity Disorder

CONCLUSIONS: These results indicate that patients with ADHD are likely to benefit from treatment with viloxazine ER, and are unlikely to discontinue, as viloxazine ER treatment was associated with favorable LHH, NNT, and NNH values. Clinicaltrials.gov: NCT03247530, NCT03247543, NCT03247517, NCT03247556.

via https://pubmed.ncbi.nlm.nih.gov/33971070/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20210526010903&v=2.14.4